Teva is quick out of the gate

The pharmaceutical company is preparing for an earlier-than-expected launch of a new generic contraceptive.

By Jim J. Jubak Jun 4, 2010 4:37PM

Jim JubakIt’s a busy month for drug announcements at Teva Pharmaceutical Industries (TEVA), with news on Copaxone, Azilect, and Gianvi -- and it’s only June 4.


Of these, Gianvi is the biggie -- at least for now.


The drug is a generic version of Bayer’s (BAYRY) oral contraceptive Yaz. Sales of Yaz came to $780 million in 2009. The contraceptive has been especially popular among younger women, since taking it produces less water retention than some other contraceptives and works to reduce acne.


But sales of Yaz have dropped recently to an annual rate of about $600 million as Bayer has cut back on advertising and promotion. (Bayer’s newest contraceptive, Natazia, was approved for sale in May.)


Teva’s launch of Gianvi comes about 13 months ahead of schedule (Wall Street was expecting a 2011 launch), and because Teva is first to file for generic rights, the company will get 180 days of marketing exclusivity.


Gianvi will add about 10 cents a share to annual earnings at Teva and with some of that already in the price, I’d estimate, I don’t see any reason to raise my target price of $66 a share by October 2010 (It traded above $53 late Thursday).


This kind of quick-to-market approach represented by the launch of Gianvi should remind us why Teva is the generic stock in Jubak’s Picks. (For more on generics and the increasing importance of emerging economies to drug makers, see this post).  


At the time of this writing, Jim Jubak owned shares of Teva Pharmaceutical Industries in his personal portfolio.

1Comment
Report
Please help us to maintain a healthy and vibrant community by reporting any illegal or inappropriate behavior. If you believe a message violates theCode of Conductplease use this form to notify the moderators. They will investigate your report and take appropriate action. If necessary, they report all illegal activity to the proper authorities.
Categories
100 character limit
Are you sure you want to delete this comment?

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

STOCK SCOUTER

StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

116
116 rated 1
284
284 rated 2
461
461 rated 3
671
671 rated 4
628
628 rated 5
618
618 rated 6
615
615 rated 7
495
495 rated 8
347
347 rated 9
115
115 rated 10
12345678910

Top Picks

SYMBOLNAMERATING
DYNDYNEGY Inc10
TAT&T Inc9
VZVERIZON COMMUNICATIONS9
EXCEXELON CORPORATION8
AAPLAPPLE Inc10
More

VIDEO ON MSN MONEY

ABOUT

Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.